Watch our webinar with Dimerix, featuring Managing Director Dr Nina Webster. An interview followed by live Q&A with the audience.

Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company developing new therapies for kidney diseases with significant unmet medical need. The Company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, Dimerix is advancing a Phase 2 program with DMX-652 in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.